At the time of writing, Genmab ADR [GMAB] stock is trading at $33.31, down -0.74%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The GMAB shares have gain 13.57% over the last week, with a monthly amount glided 20.95%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Genmab ADR [NASDAQ: GMAB] stock has seen the most recent analyst activity on September 23, 2025, when Guggenheim upgraded its rating to a Buy but kept the price target unchanged to $43 for it. Previously, Bernstein downgraded its rating to Underperform on April 01, 2025. On March 11, 2025, upgrade upgraded it’s rating to Outperform. Leerink Partners upgraded its rating to a Outperform but stick to its price target of $27 on February 13, 2025. Redburn Atlantic initiated its recommendation with a Buy. In a note dated August 20, 2024, JP Morgan downgraded an Neutral rating on this stock.
For the past year, the stock price of Genmab ADR fluctuated between $17.24 and $33.61. Currently, Wall Street analysts expect the stock to reach $41.5 within the next 12 months. Genmab ADR [NASDAQ: GMAB] shares were valued at $33.31 at the most recent close of the market. An investor can expect a potential return of 24.59% based on the average GMAB price forecast.
Analyzing the GMAB fundamentals
According to Genmab ADR [NASDAQ:GMAB], the company’s sales were 3.39B for trailing twelve months, which represents an 20.16% jump. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at 0.34%, Pretax Profit Margin comes in at 0.42%, and Net Profit Margin reading is 0.37%. To continue investigating profitability, this company’s Return on Assets is posted at 0.21, Equity is 0.25 and Total Capital is 0.21. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 32.94 points at the first support level, and at 32.58 for the second support level. However, for the 1st resistance point, the stock is sitting at 33.65, and for the 2nd resistance point, it is at 34.00.
Ratios To Look Out For
It is important to note that Genmab ADR [NASDAQ:GMAB] has a current ratio of 6.22. Also, the Quick Ratio is 6.20, while the Cash Ratio stands at 2.06. Considering the valuation of this stock, the price to sales ratio is 6.05, the price to book ratio is 3.86 and price to earnings (TTM) ratio is 16.63.
Transactions by insiders
Recent insider trading involved Klimovsky Judith V, Director, that happened on Jun 17 ’25 when 1300.0 shares were purchased.
